Crystal structure reveals curcumin‘s potential to impair cancer

636668094030536203curcumin turmeric.jpg

10 Jul 2018 --- Curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 (DYRK2) at the atomic level, leading to inhibition of DYRK2 that impairs cell proliferation and reduces cancer burden, a research team from University of California San Diego School of Medicine, Peking University and Zhejiang University have found. The research team found this previously unreported biochemical interaction through x-ray crystallography and kinase-inhibitor specificity profiling. However, before turning to curcumin or turmeric supplements, Sourav Banerjee, Ph.D., UC San Diego School of Medicine postdoctoral scholar, cautions that curcumin alone may not be the answer.

“In general, curcumin is expelled from the body quite fast,” says Banerjee. “For curcumin to be an effective drug, it needs to be modified to enter the bloodstream and stay in the body long enough to target the cancer. Owing to various chemical drawbacks, curcumin on its own may not be sufficient to completely reverse cancer in human patients.”

Click to Enlarge
A 3D image, obtained using x-ray crystallography, shows
curcumin in yellow and red binding to kinase enzyme
dual-specificity tyrosine-regulated kinase 2 (DYRK2)
in white at the atomic level.
Image credit: UC San Diego Health

Writing in the July 9 issue of the Proceedings of the National Academy of Sciences, Banerjee and colleagues report that curcumin binds to and inhibits DYRK2 leading to the impediment of the proteasome – the cellular protein machinery that destroys unneeded or damaged proteins in cells – which in turn reduces cancer in mice.

“Although curcumin has been studied for more than 250 years and its anti-cancer properties have been previously reported, no other group has reported a co-crystal structure of curcumin bound to a protein kinase target until now,” says Banerjee, first author on the study. “Because of their work on the crystallography, our collaborators at Peking University, Chenggong Ji and Junyu Xiao, helped us to visualize the interaction between curcumin and DYRK2.”

“The enzyme kinases IKK and GSK3 were thought to be the prime curcumin-targets that lead to anti-cancer effect but the co-crystal structure of curcumin with DYRK2 along with a 140-panel kinase inhibitor profiling reveal that curcumin binds strongly to the active site of DYRK2, inhibiting it at a level that is 500 times more potent than IKK or GSK3.”

Working alongside Jack E. Dixon, Ph.D., Distinguished Professor of Pharmacology, Cellular and Molecular Medicine, Chemistry and Biochemistry at UC San Diego, Banerjee and team have been looking for regulators of proteasomes to inhibit tumor formation by proteasome-addicted cancers like triple-negative breast cancer (TNBC) and the plasma cell malignancy called multiple myeloma.

Using biochemical, mouse cancer models and cellular models the team found that curcumin is a selective inhibitor of DYRK2 and that this novel molecular target has promising anticancer potential for not only chemo-sensitive but also proteasome inhibitor-resistant/adapted cancers.

“Our results reveal an unexpected role of curcumin in DYRK2-proteasome inhibition and provide a proof-of-concept that pharmacological manipulation of proteasome regulators may offer new opportunities for hard-to-treat triple-negative breast cancer and multiple myeloma treatment,” said Dixon, who was co-senior author with Zhejiang University's Xing Guo, Ph.D., on the paper. “Our primary focus is to develop a chemical compound that can target DYRK2 in patients with these cancers.”

DYRK2 depletion impairs proteasome activity and exhibits slower cancer proliferation rates and significantly reduced tumor burden in mouse models. In combination with the US FDA-approved multiple myeloma drug, carfilzomib, curcumin induced a much higher cancer cell death while normal non-cancerous cells were less affected. This suggest that targeting proteasome regulators (such as DYRK2) in combination with proteasome inhibitors may be a promising approach of anticancer therapy with less side-effects but further work is needed, according to Banerjee.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Food for thought: Suppliers on the cognitive health ingredients market 

13 Jul 2018 --- Cognitive health has proven itself a growing category, with new products appealing to consumers from all walks of life, from more senior citizens seeking to prevent cognitive decline, to busy office workers looking to combat mental fatigue. NutritionInsight speaks to suppliers about their views on this growing category.

Nutrition & Health News

“Concerning” supplement trends among Down syndrome children, study notes

03 Jul 2018 --- Research published in The Journal of Pediatrics has found that nearly half of parents of children with downs syndrome – who participated in the study – give or have given supplements to their children in an effort to improve their health outcomes. However, this information was routinely withheld from clinicians, prompting the study’s author to advise parents to proceed with caution.

Nutrition & Health News

Immunity ingredients space: From Ayurvedic roots to ocean garden

02 Jul 2018 --- The immunity ingredient space is reaching beyond classical vitamins, such as vitamin C, for immune health, with manufacturers highlighting a range of ingredients for their immune boosting properties. From Ayurvedic roots, botanicals, ocean garden's seaweed and yeast beta glucans, the market continues to diversify and expand to keep a growing market engaged. As John Quilter, Vice President and General Manager, GanedenBC & Wellmune, tells NutritionInsight, “Research shows that improving immune function is a leading health concern among consumers globally, with 87 percent expressing an interest in buying food and beverage products that deliver this benefit.”

Nutrition & Health News

One to watch: South African company tout Moringa

25 Jun 2018 --- South African supplement and natural foods company Moringa Wellness are capitalizing on what it calls, “the most nutrient-rich plant known to science”: the moringa oleifera. The health food company's food scientists have developed a process in which they use reverse osmosis and atomization to create a water-soluble botanical extract called Moringex.

Nutrition & Health News

Weekly Digest: NP Nutra triples its warehouse space, broccoli named US top vegetable

15 Jun 2018 --- This week in nutrition, research studies affirmed the benefit of vitamin K2 for healthy bones, vitamin E tocotrienol may delay paralysis associated with Alzheimers and vegetables took center stage in the US with a survey identifying broccoli as the nations favorite and large investments were made in school plant-based cafeteria options. At a sports nutrition conference, Nitrosamines positive effects on cognitive function were announced, while National Institutes of Health launched a new app aimed at providing safe information on popular herbs. Concerning expansions, NP Nutra expanded its warehouse in California and Azelis opened a new pharmaceutical manufacturing facility in Germany.

More Articles
URL : http://www.nutritioninsight.com:80/news/crystal-structure-reveals-curcumins-potential-to-impair-cancer.html